Survodutide — SEO Product Content

SEO Title

Survodutide Peptide | GLP-1 & Glucagon Dual Agonist Research

SEO Meta Description

Survodutide research peptide for studies of GLP-1 and glucagon receptor signaling, body weight, glucose metabolism, energy balance, liver fat, MASLD and MASH.

Suggested URL Slug

/product/survodutide/

SEO Product Description

Survodutide Research Peptide

Survodutide (BI 456906) is an investigational synthetic peptide designed to activate both the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R).

This dual-receptor activity makes survodutide an important research compound for investigating the interaction between incretin signaling, glucagon biology, energy metabolism, glucose regulation, body weight and liver metabolism.

Unlike selective GLP-1 receptor agonists, survodutide combines GLP-1 receptor activity with glucagon receptor activation. Preclinical pharmacological profiling identified this balanced dual activity as a key characteristic of the compound.

Pure Axis Peptides offers Survodutide as a research-use peptide for qualified laboratory and scientific investigations.

What Is Survodutide?

Survodutide is a dual glucagon receptor/GLP-1 receptor agonist being investigated in metabolic and liver-disease research.

It is also known by its development code BI 456906.

The compound provides researchers with a model for examining simultaneous activation of two important metabolic hormone pathways:

Survodutide → GLP-1 receptor + glucagon receptor → metabolic signaling

The two receptor pathways have complementary biological effects.

GLP-1 receptor activation is associated with glucose-dependent insulin secretion, appetite regulation and gastrointestinal signaling, while glucagon receptor activation influences hepatic metabolism, energy expenditure and lipid handling.

This combination makes survodutide relevant to research involving:

• GLP-1 signaling
• Glucagon signaling
• Energy metabolism
• Body-weight regulation
• Glucose homeostasis
• Hepatic metabolism
• Liver fat
• MASLD
• MASH
• Obesity biology
• Metabolic disease

Survodutide and GLP-1 Receptor Signaling

The GLP-1 receptor (GLP-1R) is a G-protein-coupled receptor involved in glucose and energy regulation.

Activation of GLP-1R can influence:

• Glucose-dependent insulin secretion
• Gastric emptying
• Appetite signaling
• Satiety
• Glucose metabolism
• Pancreatic signaling

Survodutide incorporates GLP-1 receptor activity into its dual mechanism, allowing researchers to investigate GLP-1 biology alongside glucagon receptor activation.

Survodutide and Glucagon Receptor Signaling

The glucagon receptor (GCGR) is another GPCR with a major role in metabolic regulation.

Glucagon signaling is particularly important in the liver, where it influences:

• Hepatic glucose production
• Glycogen metabolism
• Fat metabolism
• Energy expenditure
• Amino-acid metabolism

Survodutide’s GCGR activity distinguishes it from GLP-1-only agonists and provides an experimental model for studying the combined effects of incretin and glucagon signaling.

Preclinical profiling demonstrated engagement of both GCGR and GLP-1R and supported the selection of survodutide as a clinical candidate.

Survodutide and Dual Agonism

The central scientific feature of survodutide is dual agonism.

Rather than selectively activating one receptor, survodutide simultaneously targets:

GLP-1R + GCGR

Researchers are therefore able to investigate how these pathways interact to influence:

• Energy balance
• Appetite
• Glucose regulation
• Lipid metabolism
• Body weight
• Hepatic metabolism
• Liver fat

This makes survodutide part of a growing class of multi-receptor metabolic peptides.

Survodutide and Body-Weight Research

Obesity is one of the major clinical research areas for survodutide.

In the 2026 Phase 3 SYNCHRONIZE-1 trial, adults with obesity without diabetes receiving once-weekly survodutide experienced significantly greater reductions in body weight than participants receiving placebo.

At week 76, mean body-weight changes using the treatment-regimen estimand were approximately −12.2% with 3.6 mg and −13.0% with 6.0 mg, compared with −5.4% with placebo.

These findings make survodutide particularly relevant to research into:

• Body-weight regulation
• Energy balance
• Obesity biology
• Appetite signaling
• Metabolic adaptation
• Body composition

Survodutide and Obesity Research

Survodutide is being investigated extensively in obesity research.

Phase 3 studies have evaluated once-weekly survodutide in adults with obesity, with trials examining body-weight change and the proportion of participants achieving clinically meaningful weight reduction.

Research endpoints include:

• Percentage body-weight change
• Weight-loss responder rates
• Waist circumference
• Glycemic parameters
• Blood pressure
• Body composition
• Liver fat

This makes survodutide obesity research one of the strongest commercial and informational SEO clusters for the product.

Survodutide and Energy Expenditure

Glucagon receptor signaling has an important relationship with energy metabolism.

Activation of GCGR can increase metabolic activity and influence hepatic substrate utilization.

The dual GLP-1/GCGR mechanism of survodutide therefore provides a research model for investigating:

• Energy expenditure
• Substrate oxidation
• Hepatic metabolism
• Fat utilization
• Energy balance
• Metabolic adaptation

Preclinical work showed that survodutide produced substantial body-weight reductions in diet-induced obese animal models while demonstrating engagement of both target receptors.

Survodutide and Appetite Research

GLP-1 signaling has an established role in appetite and satiety pathways.

Survodutide research can therefore examine how dual GLP-1/glucagon activity influences:

• Food intake
• Satiety
• Appetite
• Energy balance
• Body-weight regulation
• Central metabolic signaling

Because survodutide combines two metabolic pathways, it is particularly useful for investigating how GLP-1-mediated appetite effects interact with glucagon-mediated metabolic signaling.

Survodutide and Glucose Metabolism

Both GLP-1 and glucagon participate in glucose homeostasis, although their physiological effects differ.

GLP-1 signaling can enhance glucose-dependent insulin secretion, while glucagon is an important regulator of hepatic glucose production.

Survodutide therefore provides an experimental system for investigating:

• Blood glucose
• Insulin secretion
• Glucagon signaling
• Hepatic glucose production
• Glycemic control
• Insulin sensitivity

Preclinical research demonstrated glucose-lowering effects in diabetic mouse models, while human clinical trials have incorporated glycemic measures among their endpoints.

Survodutide and Liver Fat

One of the most significant research areas for survodutide is hepatic steatosis, commonly referred to as liver fat.

The liver is a major target of glucagon signaling, making dual GLP-1/GCGR activation particularly interesting for metabolic liver research.

In the 2026 Phase 3 SYNCHRONIZE-MASLD trial, 84.2% of participants receiving 6.0 mg survodutide achieved at least a 30% reduction in MRI-measured liver fat using the efficacy estimand, compared with 24.3% receiving placebo.

This makes survodutide liver fat research an especially strong long-tail SEO opportunity.

Survodutide and MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic liver condition characterized by excess hepatic fat associated with metabolic dysfunction.

Survodutide has been extensively investigated in MASLD research.

The 2026 SYNCHRONIZE-MASLD Phase 3 study enrolled adults with obesity and at-risk MASLD and evaluated liver-fat reduction alongside body-weight changes. Both co-primary endpoints were met.

Potential research areas include:

• Hepatic steatosis
• Liver fat
• Metabolic dysfunction
• Insulin resistance
• Obesity-associated liver disease
• Liver inflammation
• Fibrosis risk

Survodutide and MASH

Metabolic dysfunction-associated steatohepatitis (MASH) represents a more advanced form of metabolic liver disease involving steatohepatitis and potential fibrosis.

Survodutide has generated substantial interest in MASH research.

A Phase 2 randomized trial evaluated survodutide in adults with biopsy-confirmed MASH and fibrosis stages F1-F3, examining histological improvement, liver-fat reduction and fibrosis-related outcomes.

This provides an important research pathway:

GLP-1/GCGR activation → metabolic changes → liver-fat reduction → MASH research

Survodutide and Liver Fibrosis Research

Liver fibrosis is a key outcome in progressive metabolic liver disease.

The Phase 2 MASH study specifically investigated whether survodutide could influence histological measures of MASH and fibrosis.

The relationship between metabolic improvement, hepatic fat reduction and fibrosis makes survodutide relevant to research involving:

• Hepatic fibrosis
• Liver histology
• MASH
• MASLD
• Hepatic inflammation
• Liver remodeling

Survodutide and Hepatic Metabolism

Glucagon receptor signaling is strongly associated with hepatic metabolic pathways.

Researchers can use survodutide to investigate:

• Glycogen metabolism
• Gluconeogenesis
• Lipid oxidation
• Hepatic glucose production
• Fatty-acid metabolism
• Energy substrate utilization

This provides a mechanistic explanation for why survodutide is being studied in both obesity and metabolic liver disease.

Survodutide and Lipid Metabolism

Glucagon signaling can influence lipid utilization and hepatic energy metabolism.

Dual GLP-1/GCGR agonism therefore provides a useful research model for studying:

• Fat oxidation
• Lipid mobilization
• Hepatic lipid metabolism
• Triglyceride metabolism
• Adipose-tissue metabolism
• Energy expenditure

These pathways may help explain the compound’s interest in both body-weight and liver-fat research.

Survodutide and Insulin Sensitivity

Obesity, hepatic steatosis and insulin resistance are closely interconnected.

Survodutide research can examine whether changes in body weight, liver fat and metabolic signaling are accompanied by changes in:

• Insulin sensitivity
• Glucose tolerance
• Fasting glucose
• Glycated hemoglobin
• Hepatic insulin signaling

These endpoints are particularly relevant in metabolic disease research.

Survodutide and Cardiometabolic Research

Survodutide is also being evaluated in broader cardiometabolic research.

A dedicated Phase 3 cardiovascular outcomes trial was designed to assess cardiovascular safety and efficacy in adults with overweight or obesity and elevated cardiovascular risk. The study uses major adverse cardiovascular events as its primary endpoint.

This makes survodutide relevant to research involving:

• Cardiometabolic disease
• Obesity
• Cardiovascular risk
• Blood pressure
• Metabolic biomarkers
• Cardiovascular outcomes

Survodutide and Body Composition

Beyond total body weight, researchers are interested in how metabolic peptides influence body composition.

Survodutide Phase 3 research includes body-composition investigations, including studies of fat mass and liver fat.

Potential research endpoints include:

• Fat mass
• Lean mass
• Visceral adipose tissue
• Waist circumference
• Liver fat
• Total body weight

This makes body-composition research a useful secondary SEO topic.

Survodutide and GLP-1 Peptides

Survodutide belongs to the broader family of metabolic peptides that includes GLP-1 receptor agonists.

However, survodutide is distinct because it combines:

GLP-1 receptor agonism + glucagon receptor agonism

This differentiates it mechanistically from selective GLP-1 receptor agonists such as semaglutide.

Explore Semaglutide for selective GLP-1 receptor research.

Survodutide vs. Semaglutide

The primary mechanistic distinction is receptor profile.

Survodutide

• GLP-1 receptor agonist
• Glucagon receptor agonist
• Dual agonist
• Investigated in obesity and metabolic liver disease

Semaglutide

• GLP-1 receptor agonist
• Selective GLP-1 pathway
• Extensively studied in metabolic disease and obesity

Preclinical pharmacological research directly compared survodutide’s dual-receptor activity with selective GLP-1 receptor agonism, highlighting the additional metabolic contribution of GCGR activation.

Survodutide vs. Tirzepatide

Survodutide and tirzepatide are both multi-receptor metabolic peptides, but they target different receptor combinations.

Survodutide: GLP-1R + glucagon receptor.

Tirzepatide: GLP-1R + GIP receptor.

This creates a valuable comparison for researchers studying how different combinations of metabolic hormone receptors influence body weight, glucose regulation and energy metabolism.

Explore Tirzepatide for related multi-receptor metabolic research.

Survodutide vs. Retatrutide

Survodutide and retatrutide are particularly interesting comparison targets because both incorporate glucagon receptor activity.

Survodutide: GLP-1R + GCGR.

Retatrutide: GLP-1R + GIPR + GCGR.

Retatrutide therefore adds GIP receptor activity to the GLP-1/glucagon combination.

Explore Retatrutide for triple-agonist metabolic research.

Survodutide vs. Cagrilintide

Cagrilintide operates through an entirely different metabolic pathway, primarily targeting amylin-related signaling.

This creates an interesting comparison between:

• GLP-1/glucagon signaling
• Amylin signaling
• Appetite regulation
• Energy balance
• Body-weight research

Explore Cagrilintide for related metabolic peptide research.

Survodutide and Gastrointestinal Research

Gastrointestinal adverse events have been commonly reported in clinical trials of survodutide, particularly during dose escalation.

In the 2026 Phase 3 obesity trial, gastrointestinal events were the most common adverse events and were generally mild to moderate.

This makes gastrointestinal physiology an important research consideration when studying GLP-1-based metabolic peptides.

Survodutide Research Applications

Survodutide may be relevant to laboratory studies involving:

GLP-1 Research: Investigating GLP-1 receptor signaling.

Glucagon Research: Studying glucagon receptor activation.

Dual Agonist Research: Investigating combined GLP-1/GCGR signaling.

Obesity Research: Studying body-weight regulation and energy balance.

Metabolic Research: Investigating glucose and lipid metabolism.

Liver Research: Studying hepatic metabolism and liver fat.

MASLD Research: Investigating metabolic dysfunction-associated steatotic liver disease.

MASH Research: Studying metabolic steatohepatitis and liver fibrosis.

Body-Composition Research: Investigating fat mass, lean mass and visceral adiposity.

Energy-Expenditure Research: Studying metabolic substrate utilization.

Glycemic Research: Investigating glucose homeostasis and insulin signaling.

Cardiometabolic Research: Studying obesity-associated cardiovascular risk.

Peptide Pharmacology: Investigating multi-receptor peptide agonism.

Survodutide Research Material

Researchers should verify the current Pure Axis Peptides product specification, peptide identity, sequence, purity, formulation, storage requirements and batch-specific certificate of analysis (COA) before laboratory use.

Survodutide is a pharmacologically active investigational peptide. Appropriate laboratory handling procedures and applicable institutional requirements should be followed.

Explore Related Research

Survodutide belongs within a strong metabolic peptide / multi-receptor agonist research cluster.

Explore Semaglutide for GLP-1 receptor research.

Explore Tirzepatide for GLP-1/GIP dual-agonist research.

Explore Retatrutide for GLP-1/GIP/glucagon triple-agonist research.

Explore Cagrilintide for amylin-pathway research.

Browse the Peptides collection for additional peptide research materials.

Visit Shop All Products for the complete Pure Axis Peptides catalog.

Research Use Only

Survodutide supplied by Pure Axis Peptides is intended strictly for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnosis, treatment, cure, or prevention of any disease or medical condition. Survodutide is an investigational GLP-1/glucagon receptor dual agonist and should not be represented as an approved obesity, diabetes, MASLD or MASH treatment. Clinical trial findings should not be interpreted as establishing safety or efficacy for research-grade material or for self-directed use. Researchers should evaluate all materials according to their experimental requirements, product documentation and applicable laboratory procedures.

Internal Linking Recommendations

Primary Internal Links

• Semaglutide → https://pureaxispeptides.com/product/semaglutide/
• Tirzepatide → https://pureaxispeptides.com/product/tirzepatide/
• Retatrutide → https://pureaxispeptides.com/product/retatrutide/
• Cagrilintide → https://pureaxispeptides.com/product/cagrilintide/
• Peptides → https://pureaxispeptides.com/product-category/peptides/
• Shop All Products → https://pureaxispeptides.com/shop/

Verify all live WooCommerce URLs before publishing.

Recommended Internal-Link Anchors

Use varied contextual anchors such as:

• “Survodutide research peptide”
• “survodutide research”
• “GLP-1/glucagon dual agonist”
• “dual metabolic agonist research”
• “GLP-1 research peptide”
• “glucagon receptor research”
• “metabolic peptide research”
• “obesity research peptide”
• “liver fat research”
• “MASLD research”
• “MASH research”
• “GLP-1 and glucagon research”
• “multi-receptor metabolic peptide”

Recommended Site Architecture

Build a dedicated metabolic peptide cluster:

Survodutide
→ GLP-1 receptor
→ Glucagon receptor
→ Dual agonism
→ Obesity research
→ Energy metabolism
→ Liver fat
→ MASLD
→ MASH
→ Semaglutide
→ Tirzepatide
→ Retatrutide
→ Cagrilintide

A high-value supporting article would be:

“Survodutide vs Semaglutide vs Tirzepatide vs Retatrutide: Understanding GLP-1, GIP and Glucagon Receptor Signaling”

This could become the central informational hub linking back to all four product pages.

External Scientific References

• PubMed — 2026 Phase 3 SYNCHRONIZE-1 obesity trial:
  Survodutide Once Weekly for the Treatment of Adults with Obesity — PubMed
• PubMed — 2026 Phase 3 SYNCHRONIZE-MASLD trial:
  Survodutide in Adults With Obesity and MASLD — PubMed
• PubMed — Phase 2 MASH and fibrosis trial:
  Survodutide for MASH and Fibrosis — PubMed
• PubMed — Dual GCGR/GLP-1R pharmacological profiling:
  Survodutide Pharmacological Profiling — PubMed
• PubMed — Phase 3 obesity trial design:
  SYNCHRONIZE-1 and SYNCHRONIZE-2 Trial Design — PubMed

Product Tags

Survodutide, Survodutide Peptide, Survodutide Research, Survodutide Research Peptide, BI 456906, GLP-1 Glucagon Dual Agonist, GLP-1/Glucagon Agonist, GLP-1 Research, GLP-1 Peptide, Glucagon Research, Glucagon Receptor Agonist, GCGR, GLP-1R, Dual Agonist Research, Metabolic Peptide, Metabolic Research, Obesity Research, Body Weight Research, Weight Regulation Research, Energy Metabolism, Energy Expenditure, Glucose Metabolism, Glycemic Research, Insulin Sensitivity Research, Lipid Metabolism, Liver Fat Research, Hepatic Fat Research, MASLD Research, MASH Research, Metabolic Liver Disease, Liver Fibrosis Research, Hepatic Metabolism, Body Composition Research, Visceral Adipose Research, Cardiometabolic Research, Multi-Receptor Peptide, Peptide Pharmacology, Research Peptide, Laboratory Research